Clinical trial
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen…
NCT00051935 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00051935 |
|---|---|
| Title | A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II |
| Official title | Open-Label, Pilot Study of the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Human Acid Alpha-Glucosidase (rhGAA) as Enzyme Replacement Therapy in Siblings With Glycogen Storage Disease Type II (GSD-II). |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2 |
| Intervention type | Drug |
| Interventions | Alglucosidase alfa |
| Enrollment | 2 |
| Start date | Jan 1, 2003 |
| Primary completion | Apr 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Jan 22, 2003 |
| Last update posted | Feb 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: